Several other research firms also recently weighed in on SAN. Jefferies Group LLC set a €87.00 ($101.16) target price on Sanofi SA and gave the company a neutral rating in a research report on Thursday, March 9th. Deutsche Bank AG set a €96.00 ($111.63) target price on Sanofi SA and gave the company a buy rating in a research report on Tuesday, May 2nd. J P Morgan Chase & Co set a €95.00 ($110.47) target price on Sanofi SA and gave the company a neutral rating in a research report on Thursday, June 22nd. UBS AG set a €82.00 ($95.35) target price on Sanofi SA and gave the company a neutral rating in a research report on Friday, April 28th. Finally, HSBC Holdings plc set a €77.00 ($89.53) target price on Sanofi SA and gave the company a sell rating in a research report on Friday, April 7th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of €88.00 ($102.33).
Sanofi SA (SAN) traded down 0.75% during trading on Tuesday, reaching €81.59. 2,739,458 shares of the company were exchanged. The stock has a market capitalization of €103.03 billion and a price-to-earnings ratio of 11.29. Sanofi SA has a one year low of €62.50 and a one year high of €92.97. The firm’s 50 day moving average price is €25.48 and its 200-day moving average price is €25.74.
WARNING: “Credit Suisse Group Analysts Give Sanofi SA (EPA:SAN) a €95.00 Price Target” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/07/29/sanofi-sa-epasan-pt-set-at-95-00-by-credit-suisse-group-updated-updated-updated.html.
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.